Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disparities in Cancer Care and the Asian American Population.
Lee RJ, Madan RA, Kim J, Posadas EM, Yu EY. Lee RJ, et al. Among authors: posadas em. Oncologist. 2021 Jun;26(6):453-460. doi: 10.1002/onco.13748. Epub 2021 Mar 20. Oncologist. 2021. PMID: 33683795 Free PMC article. Review.
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. Yu EY, et al. Among authors: posadas em. Urology. 2011 May;77(5):1166-71. doi: 10.1016/j.urology.2011.01.006. Urology. 2011. PMID: 21539969 Free PMC article. Clinical Trial.
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MF, Dyster LM, Carducci MA. Antonarakis ES, et al. Among authors: posadas em. Cancer Chemother Pharmacol. 2013 Apr;71(4):883-92. doi: 10.1007/s00280-013-2079-z. Epub 2013 Jan 13. Cancer Chemother Pharmacol. 2013. PMID: 23314737 Free PMC article. Clinical Trial.
SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
Gururajan M, Cavassani KA, Sievert M, Duan P, Lichterman J, Huang JM, Smith B, You S, Nandana S, Chu GC, Mink S, Josson S, Liu C, Morello M, Jones LW, Kim J, Freeman MR, Bhowmick N, Zhau HE, Chung LW, Posadas EM. Gururajan M, et al. Among authors: posadas em. Oncotarget. 2015 Dec 29;6(42):44072-83. doi: 10.18632/oncotarget.6398. Oncotarget. 2015. PMID: 26624980 Free PMC article.
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
Choueiri TK, Michaelson MD, Posadas EM, Sonpavde GP, McDermott DF, Nixon AB, Liu Y, Yuan Z, Seon BK, Walsh M, Jivani MA, Adams BJ, Theuer CP. Choueiri TK, et al. Among authors: posadas em. Oncologist. 2019 Feb;24(2):202-210. doi: 10.1634/theoncologist.2018-0299. Epub 2018 Sep 6. Oncologist. 2019. PMID: 30190302 Free PMC article. Clinical Trial.
Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure.
Alyamani M, Li J, Patel M, Taylor S, Nakamura F, Berk M, Przybycin C, Posadas EM, Madan RA, Gulley JL, Rini B, Garcia JA, Klein EA, Sharifi N. Alyamani M, et al. Among authors: posadas em. Ann Oncol. 2020 Mar;31(3):369-376. doi: 10.1016/j.annonc.2019.12.002. Epub 2020 Feb 11. Ann Oncol. 2020. PMID: 32057540 Free PMC article.
139 results